Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar
Executive Summary
HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.
You may also be interested in...
Trump’s Drug Pricing Plan: The Headlines Are The Goal – But Also A Threat
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
US Medicare Insulin Demo Could Expand To Other Drugs
Eighty-eight insurers who offer Medicare Part D plans are interested in the demonstration project, which would limit insulin copays to $35.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: